Balyasny Asset Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-130,721
| Closed | -$2.51M | – | 2442 |
|
|
2024
Q4 | $2.51M | Sell |
130,721
-208,368
| -61% | -$3.99M | ﹤0.01% | 1049 |
|
|
2024
Q3 | $7.71M | Buy |
+339,089
| New | +$7.71M | 0.01% | 745 |
|
|
2024
Q1 | – | Sell |
-41,214
| Closed | -$898K | – | 2469 |
|
|
2023
Q4 | $898K | Buy |
41,214
+27,245
| +195% | +$593K | ﹤0.01% | 1242 |
|
|
2023
Q3 | $214K | Buy |
+13,969
| New | +$214K | ﹤0.01% | 1535 |
|
|
2023
Q1 | – | Sell |
-304,552
| Closed | -$8.9M | – | 2677 |
|
|
2022
Q4 | $8.9M | Buy |
304,552
+135,023
| +80% | +$3.94M | 0.02% | 607 |
|
|
2022
Q3 | $3.48M | Buy |
+169,529
| New | +$3.48M | 0.01% | 909 |
|
|
2022
Q2 | – | Sell |
-16,303
| Closed | -$301K | – | 2734 |
|
|
2022
Q1 | $301K | Buy |
+16,303
| New | +$301K | ﹤0.01% | 1572 |
|
|
2021
Q3 | – | Sell |
-119,478
| Closed | -$2.19M | – | 2110 |
|
|
2021
Q2 | $2.19M | Sell |
119,478
-98
| -0.1% | -$1.79K | 0.01% | 871 |
|
|
2021
Q1 | $2M | Buy |
+119,576
| New | +$2M | 0.01% | 860 |
|